Certainly. Below is a **detailed, structured, and comprehensive summary** of the *Patented Medicines (Notice of Compliance) Regulations*, S.C. 1993, c. 2, s. 4, as amended and interpreted in the context of Canadian patent and drug regulation.

---

## ğŸ“š **Detailed Summary of the Patented Medicines (Notice of Compliance) Regulations**

### **1. Purpose and Legal Basis**
These regulations implement **section 55.2(4)** of the *Patent Act* and are made by **His Excellency the Governor General in Council**, on the recommendation of the **Minister of Consumer and Corporate Affairs** (now the Minister of Health).  
They establish a framework for how **patents on patented medicines** are evaluated and managed in relation to **new drug submissions** and **supplements** under the *Food and Drug Regulations (FDR)*.

The primary objective is to **ensure that only valid, relevant, and properly authorized patents are included in a public register**, thereby protecting innovators while allowing generic manufacturers to enter the market after appropriate compliance with patent rights.

> **Regulation Title**: *Patented Medicines (Notice of Compliance) Regulations*  
> **Citation**: S.C. 1993, c. 2, s. 4

---

### **2. Key Definitions**

| Term | Definition |
|------|-----------|
| **Claim for the dosage form** | A claim covering a delivery system (e.g., tablet, injection) that administers a medicinal ingredient or formulation. Includes the ingredient or formulation within its scope. |
| **Claim for the formulation** | A claim for a mixture of medicinal and non-medicinal ingredients contained in a drug and administered in a specific dosage form. *Does not need to specify non-medicinal ingredients.* |
| **Claim for the medicinal ingredient** | Includes chemical or biological substances claimed in a patent, produced via the methods described in the patent or their "obvious equivalents," and includes different **polymorphs** of the ingredient. *Excludes different chemical forms.* |
| **Claim for the medicine itself** | *Repealed* (SOR/2006-242, s.1) |
| **Claim for the use of the medicinal ingredient** | A claim for using the ingredient to diagnose, treat, mitigate, or prevent a disease, disorder, or symptom. |
| **Court** | *Repealed* (SOR/2017-166, s.1) |
| **Expire** | Means the patent or certificate of supplementary protection lapses or terminates by operation of law. |
| **First person** | The person who files the original new drug submission or supplement. |
| **Second person** | A person filing a new drug submission or supplement that directly or indirectly compares their drug to one previously approved (marketed) under a notice of compliance where a patent list exists. |
| **Identification number (DIN)** | A unique number (e.g., DIN-123456) assigned to a drug under FDR, C.01.014.2(1). |
| **New drug submission** | A submission for a new drug or an extraordinary use (e.g., new indication), excluding changes in manufacturer name. |
| **Supplement to a new drug submission** | A change in formulation, dosage form, or use; excludes changes based only on manufacturer name. |
| **Register** | A public register maintained by the Minister of Health listing patents and certificates of supplementary protection eligible for inclusion. |
| **Patent list** | A document submitted by the first person listing all relevant patents for a drug submission. |

> âš ï¸ **Note**: Several definitions (e.g., "medicine," "court") have been **repealed** and are no longer in force.

---

### **3. The Register: Management and Maintenance**

The **Minister of Health** maintains a **public register** of:
- Patents and certificates of supplementary protection (CSPs)
- That meet eligibility criteria
- That are linked to new drug submissions or supplements

#### **Actions the Minister May Take Regarding the Register:**

| Action | Conditions |
|-------|-----------|
| âœ… **Add** a patent/CSP | If it meets eligibility requirements and a notice of compliance has been issued for the related submission. |
| âŒ **Refuse to add** | If the patent does not meet eligibility criteria. |
| ğŸ” **Delete** a patent/CSP | If: <br> - It was added due to an administrative error; <br> - It has been declared invalid/void under s.60(1) or s.125(1) of the Patent Act; <br> - It has been declared ineligible under s.6.07(1); <br> - The first person requests deletion; <br> - The patent has expired (unless a CSP covers it); <br> - The CSP has expired. |

> ğŸ” **Important Restriction**:  
> The Minister **cannot delete** a patent based on a Federal Court decision **before the later of**:  
> - The deadline for appealing to the Federal Court of Appeal;  
> - The date when the appeal is discontinued or dismissed.  
> This protects patent rights during judicial review.

> âœ… If a deletion is later **reversed on appeal**, the patent/CSP is **re-added** to the register.

> ğŸ”„ The Minister may **review** the register to remove any patent/CSP that fails to meet eligibility standards.

> â³ If a drug's **identification number (DIN)** is cancelled under **C.01.014.6(1)(a)** (e.g., due to a change in manufacturer), the related patent is deleted from the register **90 days after cancellation**.

> âœ… **Exception**: If the DIN is cancelled due to a manufacturer change, subsection (3) does **not apply**.

> âœ… If a new DIN is assigned to the same drug after cancellation, the previously deleted patent is **re-added** when the required documentation under **C.01.014.3** is received.

#### **Public Access**
- The register is **open to public inspection during business hours**.

---

### **4. Eligibility Criteria for Adding a Patent to the Register**

A patent may be added to the register **only if**:

#### For a **new drug submission**:
The patent must contain **one of the following claims** and the corresponding claim must have been approved via a **notice of compliance**:

| Claim Type | Eligibility Condition |
|----------|------------------------|
| **Medicinal ingredient** | The ingredient must be approved (via notice of compliance). Even if other ingredients are present in the submission. |
| **Formulation** | The formulation must be approved. The claim may include non-medicinal ingredients; even if other non-medicinal ingredients are present. |
| **Dosage form** | The dosage form must be approved. |
| **Use of ingredient** | The use (diagnosis, treatment, etc.) must be approved. The use may be broader than the submission (e.g., combination with another drug), or include additional ingredients. |

> âœ… **Flexibility**:  
> - A patent may include **additional ingredients** beyond those claimed â€” still eligible.  
> - A patent may include **additional uses** â€” still eligible.  
> - A patent may include **combination therapy** â€” still eligible.

#### For a **supplement to a new drug submission**:
The supplement must involve a **change in**:
- Formulation
- Dosage form
- Use of the ingredient

And the patent must contain a claim for the **changed version** that has been approved via a **notice of compliance** for the supplement.

> Example: A supplement requesting a new tablet formulation â€” the patent must claim that formulation and must have been approved in the supplement.

#### For a **Certificate of Supplementary Protection (CSP)**:
- The underlying patent must be **on the register** for that submission or supplement.
- The CSP must grant rights, privileges, or liberties under **section 115 of the Patent Act** (i.e., it must extend protection for the drug).

> CSPs are only eligible if they are tied to a valid, registered patent and relate to a drug with a valid submission.

---

### **5. Requirements for a Patent List**

A patent list must include:

1. Identification of the **new drug submission or supplement**.
2. Details of the drug:  
   - Medicinal ingredient  
   - Brand name  
   - Dosage form  
   - Strength  
   - Route of administration  
   - Use  
3. For each patent:  
   - Patent number  
   - Filing date in Canada  
   - Date of grant  
   - Expiration date  
4. Statement from the **first person** that they are:  
   - The owner of the patent, or  
   - Hold an exclusive licence, or  
   - Have obtained the ownerâ€™s consent to include the patent.  
5. Address for service (for legal notices) or name/address of an alternate party.  
6. Certification that:  
   - All information is accurate  
   - Each patent meets eligibility requirements

> âœ… **Submission Timing**:
> - Must be submitted **at the time of filing** of the new drug submission or supplement (subsection 4(2)).
> - Alternatively, within **30 days** after a patent is issued (based on a Canadian filing date prior to submission filing).

> ğŸ” **Resubmission**:  
> A first person may resubmit the **same patent list** in relation to a **supplement**, but **cannot submit a new list